Most recently, Dr. Lalezari was principal investigator of CytoDyn’s Phase 2 and Phase 3 PRO 140 investigative monotherapy trial. It is a  considerable achievement for patients’ opportunity for option to maintain HIV viral load suppression. CytoDyn is filing an...